Health & Nutrition
FNArena Windows (Sectors)
Introduction to FNArena Windows
The New Criterion’s Tim Boreham highlights some interesting health and wellness stocks to monitor
Apr 29 2021
Having completed its efficiency drive, Sigma Healthcare is looking to M&A to enable future growth
Mar 24 2021
|ASX CODE||COMPANY NAME||LAST PRICE||52WK HIGH||52WK LOW||P/E||CONSENSUS TARGET|
|API||AUSTRALIAN PHARMACEUTICAL INDUSTRIES LIMITED||$1.53||$1.55||$1.06||20.2||
|CLV||CLOVER CORPORATION LIMITED||$1.59||$1.98||$1.17||30.3||
|EBO||EBOS GROUP LIMITED||$33.99||$37.00||$23.13||27.1||
|SIG||SIGMA HEALTHCARE LIMITED||$0.57||$xx.xx||$xx.xx||xx.x||xx.xx|
Nov 04 2020
McPherson’s has expanded into the herbal product segment by acquiring Global Therapeutics and can now build out that business across its pharmacy distribution channel.
Sep 23 2020
Peter Switzer of the Switzer Report highlights nine stocks that aren’t his top picks, but that analysts believe offer solid upside ahead.
Sep 11 2020
A brief look at important company events and economic data releases next week
Dec 17 2019
Sigma Healthcare has adjusted guidance to account for the renewed Chemist Warehouse contract, while Australian Pharmaceutical Industries finally takes its hat out of the merger ring.
Nov 01 2019
Blackmores’ first half profit warning has sent analysts into a scramble to downgrade forecasts, but turnaround potential has been boosted by a shift in strategy.
Apr 17 2019
Elevated inventory persisted over the March quarter amid falling sales for Blackmores, which has recognised the need to reposition its business to better cater for the Chinese market.
Dec 17 2018
A merger of Australian Pharmaceutical Industries and Sigma Healthcare is logical but ACCC issues are uppermost in broker views.
Sep 11 2018
Uncertainty is likely to hinder Sigma Pharmaceuticals until a firm earnings base is established after the exit of its major customer.
Jul 03 2018
Stockbrokers are still not keen on buying Sigma Healthcare shares, though a capital return might change their view.
Apr 27 2018
Several issues, mostly one-off, plagued Blackmores in the March quarter and some brokers query whether the growth profile justifies the elevated valuation.
Oct 27 2021 - Daily Market Reports
Oct 27 2021 - Australia
Oct 27 2021 - Australia
Oct 27 2021 - Weekly Reports
Oct 27 2021 - Feature Stories
Oct 05 2021 - Technicals
Oct 05 2021 - Weekly Reports
The Wrap: Artificial Intelligence, Construction Industry, Rising Bond Yield Winners & Small Cap Ideas
Oct 01 2021 - Weekly Reports
Oct 14 2021 - Rudi's View
Sep 28 2021 - Weekly Reports
Oct 21 2021 - Rudi's View